At Paraza, we don’t just execute science, we explain it with clarity, rigor, and purpose. Our white papers showcase the insights, methodologies, and innovations driving our work across discovery and development. Each publication delivers technical depth, strategic context, and fresh perspectives on emerging scientific challenges, offering direct access to the expertise shaping research at Paraza. Explore how our teams transform complex science into actionable insight.
Following initial biochemical characterization, cellular assays demonstrating on-target activity are essential to confirm that compounds bind to their intended target within the complex cellular environment, where permeability, metabolism, and intracellular localization affect efficacy. Understanding compound pharmacodynamics in cellular and in-vivo contexts are critical steps to support informed decision-making during lead optimization and preclinical development.
PROTAC® or molecular glues rely on the ubiquitin proteasome system (UPS) to degrade their target protein. Our biology department offers a suite of assays to develop and characterize this new class of therapeutic agents and has already supported more than 16 projects for targeted protein degradation drug development, providing flexible and know-how expertise. Paraza Pharma chemistry team can support PROTAC® and glue design and synthesis, while our DMPK team is ready to profile physicochemical properties/ADME/PK.
High-throughput viability assays are a cornerstone of screening cascades to guide SAR in oncology drug development. In the early stages of drug discovery, cell-based assays are indispensable for understanding the functional effects of new therapeutic agents. Our portfolio encompasses high-throughput assays to assess fundamental cell health indicators such as proliferation, viability and cytotoxicity, as well as more complex assays to quantify cell cycle alterations, senescence, apoptosis and more.
DNA damage is one of the most ubiquitous mechanisms of action exploited in cancer therapy. Rapid proliferation rates and the presence of damaging mutations in DNA repair pathway genes make cancer cells highly susceptible to insult to their genomic material, and classic radiation and chemotherapy treatments exploit this weakness. More targeted approaches to induce damage or prevent repair seek to overcome resistance by exploiting new targets. Conversely, DNA damage quantification is crucial to determine potential genotoxicity of new compounds, which is a key concern in assessing their safety profile.